Atossa Therapeutics, Inc. stock is up 13.18% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 11 December’s closed higher than November.
Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.